Alembic Pharma’s Q4FY22 Quarter Results
Alembic Pharma’s net revenues grew 9% YoY in Q4FY22.
- 02 May 2022
- Alembic Pharma’s consolidated revenues for the quarter ended December (Q4FY22) were up 11% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
- Its expenses for the quarter were up 27% QoQ and 37% YoY.
- While the company reported a 80% QoQ net profit decline, the same was down by 86% on a YoY basis.
- The earnings per share (EPS) of Alembic Pharma stood at 1.8 during Q4FY22.
Alembic Pharma’s Financial Statements for Q4FY22:
(Rs, crores)
Total Income
Q4FY21
1,306
Q3FY22
1,287
Q4FY22
1,426
QoQ (%)
11%
YoY (%)
9%
(Rs, crores)
Total Expenses
Q4FY21
1,014
Q3FY22
1,090
Q4FY22
1,385
QoQ (%)
27%
YoY (%)
37%
(Rs, crores)
Profit before tax
Q4FY21
292
Q3FY22
197
Q4FY22
41
QoQ (%)
-79%
YoY (%)
-86%
(Rs, crores)
Tax
Q4FY21
54
Q3FY22
32
Q4FY22
-2
QoQ (%)
-
YoY (%)
-
(Rs, crores)
Profit after tax
Q4FY21
251
Q3FY22
176
Q4FY22
35
QoQ (%)
-80%
YoY (%)
-86%
(Rs, crores)
Earnings per share
Q4FY21
12.8
Q3FY22
9.0
Q4FY22
1.8
QoQ (%)
YoY (%)
| (Rs, crores) | Q4FY21 | Q3FY22 | Q4FY22 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
| Total Income | 1,306 | 1,287 | 1,426 | 11% | 9% |
| Total Expenses | 1,014 | 1,090 | 1,385 | 27% | 37% |
| Profit before tax | 292 | 197 | 41 | -79% | -86% |
| Tax | 54 | 32 | -2 | - | - |
| Profit after tax | 251 | 176 | 35 | -80% | -86% |
| Earnings per share | 12.8 | 9.0 | 1.8 |
Data Source: BSE, Company announcements
Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Open Demat Account
or Resume your Application
